Moore RD - Search Results

1

Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.

Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, Gallant JE, Cofrancesco J Jr, Moore RD, Gange SJ, Siliciano RF. Siliciano JD, et al. Among authors: moore rd. J Infect Dis. 2007 Mar 15;195(6):833-6. doi: 10.1086/511823. Epub 2007 Jan 30. J Infect Dis. 2007. PMID: 17299713

2

Anemia in HIV-infected patients receiving highly active antiretroviral therapy.

Moore RD, Forney D. Moore RD, et al. J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):54-7. doi: 10.1097/00042560-200201010-00007. J Acquir Immune Defic Syndr. 2002. PMID: 11782590

3

Hepatitis C and progression of HIV disease.

Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Sulkowski MS, et al. Among authors: moore rd. JAMA. 2002 Jul 10;288(2):199-206. doi: 10.1001/jama.288.2.199. JAMA. 2002. PMID: 12095384

4

Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort.

Perez JL, Moore RD. Perez JL, et al. Among authors: moore rd. Clin Infect Dis. 2003 Jan 15;36(2):212-8. doi: 10.1086/345669. Epub 2003 Jan 6. Clin Infect Dis. 2003. PMID: 12522755

5

Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity.

Sterling TR, Chaisson RE, Moore RD. Sterling TR, et al. Among authors: moore rd. Clin Infect Dis. 2003 Mar 15;36(6):812-5. doi: 10.1086/367934. Epub 2003 Feb 27. Clin Infect Dis. 2003. PMID: 12627368

6

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.

Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Sethi AK, et al. Among authors: moore rd. Clin Infect Dis. 2003 Oct 15;37(8):1112-8. doi: 10.1086/378301. Epub 2003 Sep 19. Clin Infect Dis. 2003. PMID: 14523777

7

Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.

Sterling TR, Chaisson RE, Keruly J, Moore RD. Sterling TR, et al. Among authors: moore rd. J Infect Dis. 2003 Dec 1;188(11):1659-65. doi: 10.1086/379741. Epub 2003 Nov 14. J Infect Dis. 2003. PMID: 14639536

8

Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study.

Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Lucas GM, et al. Among authors: moore rd. AIDS. 2004 Feb 20;18(3):541-6. doi: 10.1097/00002030-200402200-00022. AIDS. 2004. PMID: 15090808

9

Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study.

Lucas GM, Weidle PJ, Hader S, Moore RD. Lucas GM, et al. Among authors: moore rd. Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S409-13. doi: 10.1086/421405. Clin Infect Dis. 2004. PMID: 15156431 Clinical Trial.

10

Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing.

Lucas GM, Gallant JE, Moore RD. Lucas GM, et al. Among authors: moore rd. AIDS. 2004 Jul 23;18(11):1539-48. doi: 10.1097/01.aids.0000131339.68666.1a. AIDS. 2004. PMID: 15238772

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

930 results

Search Page

Filters